Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Recombinant factor VIIa: Safety and efficacy
Lawrence T. Goodnough
, Aryeh S. Shander
Icahn School of Medicine at Mount Sinai
Research output
:
Contribution to journal
›
Review article
›
peer-review
32
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Recombinant factor VIIa: Safety and efficacy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adult Patients
14%
Beneficial Effects
14%
Consensus Recommendations
14%
Disseminated Intravascular Coagulation
14%
Diverse Patient Population
14%
Excessive Bleeding
28%
Hemorrhagic Stroke
14%
Hemostasis
14%
Hemostatic Effect
14%
Hemostatic System
14%
Hypercoagulability
14%
Number of Patients
14%
Off-label Use
14%
Patients with Liver Disease
14%
Pharmaceutics
14%
Recombinant Activated Factor VII (rFVIIa)
100%
Safety Cost
14%
Safety Efficacy
14%
Transfusion
14%
Vitamin K
14%
Vitamin K Antagonist Therapy
14%
Warfarin
14%
Medicine and Dentistry
Bleeding
28%
Blood Stasis
14%
Cerebral Hemorrhage
14%
Disseminated Intravascular Coagulation
14%
Health Care Cost
14%
Hemostat
28%
Hypercoagulability
14%
Liver Disease
14%
Off-Label Use
14%
Patient Population
14%
Recombinant Blood Clotting Factor 7a
100%
Vitamin K Antagonist
14%
Warfarin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Antivitamin K
14%
Bleeding
28%
Blood Stasis
14%
Brain Hemorrhage
14%
Disseminated Intravascular Clotting
14%
Hemostatic Agent
28%
Hypercoagulability
14%
Liver Disease
14%
Off-Label Use
14%
Recombinant Blood Clotting Factor 7a
100%
Vitamin K Group
14%
Warfarin
14%